EGFR Signaling Networks in Cancer Therapy (Cancer Drug Discovery and Development)

The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies. Over decades of study, the EGF receptor structure, its ligand binding domains, the physical biochemistry underlying its intrinsic tyrosine kinase catalytic function and the modular interactions with SH2, PTB, and SH3 domain containing signaling adaptor p- teins required for signal transduction, have been extensively dissected. Not only is the EGF receptor the nexus of many streams of information, but it also forms one part of a calcul- ing device by forming dimers and oligomers with the other three receptors in its family in response to at least eleven ligands (some of which are expressed in multiple forms with overlapping or quite distinct functions). This phenomenon, while recruiting to the inner surface of the cell membrane and activating multiple second messenger proteins, also allows the possibility of cross talk between these systems, permitting a further layer of information to be exchanged. Less well described are the cross re gulation of the EGF receptor and other anti-apoptotic, mitogenic and metabolic signaling systems. The study of these systems has yielded new surprises. One hurdle in these efforts has been that signal transduction pathways have frequently been defined in the generic absence of their tissue-specific or cell-interaction specific context. The epidermal growth factor (EGF) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGFR therapies. EGFR Signaling Networks in Cancer Therapy is separated into two sections, the first of which probes the molecular pathways and the intersection of signaling networks, which are frequently deregulated in human cancers, with a view to describing the EGF receptor in a tumor tissue-specific context. The second section illustrates the many ways in which EGF receptors contribute to abnormal survival and migration signaling in cancer cells and to epithelial to mesenchymal transition and metastasis. The book also describes the mitogenic, survival, adhesive and migratory pathways within a framework of interacting subsystems that contribute to the activity and physiological regulation of the receptor in normal and neoplastic tissues. Even though there is still much to learn, this volume explores this fascinating system and provides compelling information. Probes the molecular pathways and the intersection of signaling networks, which are frequently deregulated in human cancers, Describes EGF receptor in a tumor tissue-specific context, Illustrates the many ways in which EGF receptors contribute to abnormal survival and migration signaling in cancer cells and to epithelial-to-mesenchymal transition and metastasis The epidermal growth factor (EGF) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGFR therapies. Edited by John Haley and William J. Gullick, EGFR Signaling Networks in Cancer Therapy, is separated into two sections. The first of which probes the molecular pathways and the intersection of signaling networks which are frequently deregulated in human cancers, with a view to describing EGF receptor in a tumor tissue specific context. Meanwhile, the second section illustrates the many ways in which EGF receptor contribute to abnormal survival and migration signaling in cancer cells and to epithelial to mesenchymal transition and metastasis. The book also describes the mitogenic, survival, adhesive and migratory pathways within a framework of interacting subsystems that contribute to the activity and physiological regulation of the receptor in normal and neoplastic tissues. Even though there is still much to learn, this volume explores this fascinating system with compelling information Haley_FM.pdf Haley_Ch01.pdf Haley_Ch02.pdf Haley_Ch03.pdf Haley_Ch04.pdf Haley_Ch05.pdf Haley_Ch06.pdf Haley_Ch07.pdf Haley_Ch08.pdf Haley_Ch09.pdf Haley_Ch10.pdf Haley_Ch11.pdf Haley_Ch12.pdf Haley_Ch13.pdf Haley_Ch14.pdf Haley_Ch15.pdf Haley_Ch16.pdf Haley_Ch17.pdf Haley_Ch18.pdf Haley_Ch19.pdf Haley_Ch20.pdf Haley_Ch21.pdf Haley_Ch22.pdf Haley_Ch23.pdf Haley_index.pdf Haley_CP.pdf Edited By John D. Haley, William John Gullick. Includes Bibliographical References And Index.